Molecular Name: Cefiderocol 
Active Ingredient: Cefiderocol 
Strength:1g per vial,  injection, powder for solution
Manufacturer Name :  

For adults with few other treatment options, the drug cefiderocol has been developed to treat infections brought on by aerobic Gram-negative organisms that are multi-drug (MDR) or extensively drug (XDR) resistant.

In order to treat patients with complicated urinary tract infections (cUTI), including kidney infections caused by susceptible Gram-negative microorganisms, who have few or no other treatment options, Fetroja (cefiderocol) in India, is used as an antibacterial medication.

To put it another way, Cefiderocol is indicated for treating bacterial pneumonia acquired in a clinic setting and pneumonia related to the use of a ventilator and caused by any of the susceptible Gram-negative microorganisms.

Most crucially, Cefiderocol in India should only be used to treat or prevent diseases that are proven or strongly suspected to be caused by susceptible bacteria to reduce the development of drug-resistant bacteria and maintain the viability of Cefiderocol and other antibacterial medications. Get cefiderocol in India at the best price from us, ARKON SOLUTIONS, through Name patient Import Services or Govt Hospital Supply

Pharmaceutical Particulars

List of excipients

Special storage precautions

Pharmaceutical Particulars


Cefepime injections are employed to treat bacterial infections in numerous body areas. Cefiderocol is a component of the cephalosporin type of antibiotics. It either prevents microbial growth or gets rid of it best. A shot of this medication is administered into a muscle or vein. Cefiderocol injection treats complicated urinary tract infections, including pyelonephritis, in patients with limited or no other treatment options. Cefepime injection can be used to treat a variety of bacterial infections, even ones that are serious or life-threatening. The benefit of this medicine is an antibiotic. Like other -lactam antibiotics, cefiderocol can penetrate bacterial cells via porins through passive diffusion.

Patients with a history of severe hypersensitivity to cefiderocol, other beta-lactam antibiotics, or any other Cefiderocol ingredient should not use the medication. Adults with few other options for therapy can use Cefiderocol to treat infections caused by aerobic Gram-negative bacteria. Diarrhea, vomiting, nausea and cough were the most frequent adverse effects, which could affect up to 1 in 10 people. Consult the product brochure for a complete list of Cefiderocol’s adverse effects. Patients hypersensitive to any cephalosporin antibiotic or who have experienced a severe reaction to the larger class of beta-lactam antibiotics should not use Cefiderocol such as penicillins or carbapenems. You can see the packaging booklet for a complete list of restrictions.

Cefiderocol should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria to avoid the development of drug-resistant bacteria and maintain the efficacy of Cefiderocol and other antibacterial medications. For intravenous (IV) infusion, Cefiderocol is offered as a white to off-white, sterile, one gramme of cefiderocol lyophilised powder for reconstitution in a clear single-dose glass vial. Passive diffusion allows for the entry of Cefiderocol and other beta-lactams into the periplasm and porin channels in the outer membrane of bacterial cells. Cefiderocol can also actively enter bacterial cells by using the iron transport mechanism.

Cefiderocol in India is prescribed for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis caused by the accompanying susceptible Gram-negative microorganisms Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex, cefiderocol is shown in patients 18 years of age or older.

  1. Cefiderocol is provided at a reasonable injection price in India, It comes in a pack of 10 vials per box 1gram strength per vial.
  2. Doses between 20 and 100 mg are possible.
  3. The powder should be reconstituted with either 10 mL of sodium chloride 9 mg/ml (0.9 percent) solution for injection or 10 mL of 5 percent dextrose injection, both of which should be taken from the 100 mL bags that will be used to make the final infusion solution.
  4. The mixture should be gently shaken to dissolve the powder. The vial(s) must be left standing until the foam that formed on the surface has subsided (typically within 2 minutes). The reconstituted solution’s final volume in the vial will be roughly 11.2 mL.
  5. The reconstituted solution is not for direct injection.
  6. There should be no shaking of the vials.
  7. Cefiderocol is an unpreserved, sterile solution. Only for one use.
  8. Do not tremble. Before injecting, let the vials come to room temperature.
  9. Visually check the solution for impurities and discolouration before administering it and if you see any particles floating, do not use it.
  10. From a microbiological point of view, unless the method of opening/reconstitution precludes the risk of microbial contamination, the reconstituted product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and should not be more than 1 hour at 25°C.
  11. Waste and unused medications should be disposed of according to local regulations.

Patients with a history of severe hypersensitivity to cefiderocol, other beta-lactam antibiotics, or other Cefiderocol ingredients should not take Cefiderocol.

  •  Elevations in liver tests
  •  Hypokalemia
  •  Constipation
  •  Nausea
  •  Diarrhea
  •  Vaginal Yeast Infections
  •  Headache
  •  Rash
  •  Vomiting
  •  Cough
  •  Injection Site Reactions